Literature DB >> 25841630

Distribution of the orexin-1 receptor (OX1R) in the mouse forebrain and rostral brainstem: A characterisation of OX1R-eGFP mice.

Sarah Sulaiman Ch'ng1, Andrew J Lawrence2.   

Abstract

We have utilised a transgenic reporter mouse in which green fluorescent protein (GFP) expression is driven by the orexin-1 receptor (OX1R) promoter to systematically map the distribution of OX1R-expressing neurons throughout the mouse forebrain and rostral brainstem. GFP labelling was observed in perikarya and fibres in an extensive range of brain loci encompassing the olfactory and cerebral cortices, dorsal and ventral pallidum, hippocampus, amygdaloid regions, septal areas, thalamic nuclei, hypothalamic nuclei and several brainstem regions, consistent with previous studies of OX1R mRNA expression. This is the first study to systematically characterise the neuroanatomical distribution of OX1R in the OX1R-eGFP mouse, confirming its veracity as a faithful reporter of OX1R expression and utility for future studies assessing the role of OX1R in more complex behaviours.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Green fluorescent protein; Immunohistochemistry; Orexin; Orexin-1 receptor

Mesh:

Substances:

Year:  2015        PMID: 25841630     DOI: 10.1016/j.jchemneu.2015.03.002

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  17 in total

1.  Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling.

Authors:  K A Levy; Z D Brodnik; J K Shaw; D A Perrey; Y Zhang; R A España
Journal:  Psychopharmacology (Berl)       Date:  2017-06-30       Impact factor: 4.530

2.  The Role of Orexin Signaling in the Ventral Tegmental Area and Central Amygdala in Modulating Binge-Like Ethanol Drinking Behavior.

Authors:  Jeffrey J Olney; Montserrat Navarro; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2017-02-09       Impact factor: 3.455

Review 3.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

4.  Excitation of Cortical nNOS/NK1R Neurons by Hypocretin 1 is Independent of Sleep Homeostasis.

Authors:  Rhîannan H Williams; Sarah W Black; Alexia M Thomas; Juliette Piquet; Bruno Cauli; Thomas S Kilduff
Journal:  Cereb Cortex       Date:  2019-03-01       Impact factor: 5.357

5.  Orexin in Rostral Hotspot of Nucleus Accumbens Enhances Sucrose 'Liking' and Intake but Scopolamine in Caudal Shell Shifts 'Liking' Toward 'Disgust' and 'Fear'.

Authors:  Daniel C Castro; Rachel A Terry; Kent C Berridge
Journal:  Neuropsychopharmacology       Date:  2016-01-20       Impact factor: 7.853

6.  Morphological and Physiological Interactions Between GnRH3 and Hypocretin/Orexin Neuronal Systems in Zebrafish (Danio rerio).

Authors:  Yali Zhao; Chanpreet Singh; David A Prober; Nancy L Wayne
Journal:  Endocrinology       Date:  2016-08-17       Impact factor: 4.736

Review 7.  Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect.

Authors:  Steven J Simmons; Taylor A Gentile
Journal:  Brain Res       Date:  2019-02-20       Impact factor: 3.252

Review 8.  Role of Orexin-A in Hypertension and Obesity.

Authors:  Roberta Imperatore; Letizia Palomba; Luigia Cristino
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

9.  Involvement of orexin/hypocretin in the expression of social play behaviour in juvenile rats.

Authors:  Christina J Reppucci; Cassandra K Gergely; Remco Bredewold; Alexa H Veenema
Journal:  Int J Play       Date:  2020-02-09

10.  Activation of lateral hypothalamic group III metabotropic glutamate receptors suppresses cocaine-seeking following abstinence and normalizes drug-associated increases in excitatory drive to orexin/hypocretin cells.

Authors:  Jiann W Yeoh; Morgan H James; Cameron D Adams; Jaideep S Bains; Takeshi Sakurai; Gary Aston-Jones; Brett A Graham; Christopher V Dayas
Journal:  Neuropharmacology       Date:  2018-09-22       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.